Advaxis

Drug developer Advaxis Inc’s shares up as much as 38%

Drug developer Advaxis Inc’s shares up as much as 38%

On Wednesday, drug developer Advaxis Inc said that the US Food and Drug Administration had lifted a clinical ban on its three experimental cancer therapies. The move has sent the shares of the company up by as much as 38%.

In October, the US health regulator had put the mid-stage trials of the lead therapy of the company, axalimogene filolisbac, on hold following the death of a patient.

Then, Advaxis said that the patient has died because of progression of cervical cancer and no role was played by the drug in life loss. Later, the FDA put a clinical hold on all three therapies in the drug developer's pipeline.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate


Syndicate content